Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Yoshi Itoh, Associate Professor and Principal Investigator Cell Migration Group at the Kennedy Institute has been awarded the International Dupuytren Award 2022.

Yoshi Itoh Dupuytren's award
Yoshi Itoh (r) receives the International Dupuytren award 2022 from Dominic Furniss (l)

Yoshi's paper: “A common SNP risk variant MT1-MMP causative for Dupuytren’s disease has a specific defect in collagenolytic activity”, published in Matrix Biology was recognised as the best paper published on the subject of Dupuytren's Disease in the previous year.

On receiving the award Yoshi said: “It is wonderful that our discovery was recognised by the International Dupuytren Society. I feel very honoured to receive the International Dupuytren's Award 2022. Our study demonstrated that one of the causes of Dupuytren disease is the impaired collagen catabolism caused by the single nucleotide polymorphism at the gene of the crucial cell surface collagenolytic enzyme, MT1-MMP/MMP-14. We hope that our discovery will lead to the development of novel therapeutics for Dupuytren disease in the future.

"Around 30% of the worldwide population or 35% of the European population have the low collagenolytic SNP allele. Therefore, further investigation on the impact of the SNP in different pathophysiological conditions is very important. Finally, I wish to express my appreciation to all the authors of the paper. Without everyones’ contributions, it would have been impossible to complete the paper.”

Professor Dominic Furniss, who presented Yoshi with the award said: “My congratulations go to Yoshi for this recognition of his research by the International Dupuytren Society. This is the sixth year running that a team from NDORMS has won the award, which demonstrates our world leading research in this area.”

The International Dupuytren Award recognises exceptional scientific publications on research or clinical treatment of Dupuytren and/or Ledderhose disease. 

Similar stories

£1.2M to improve diagnosis of emergency spinal condition

The National Institute for Health and Care Research has awarded an Advanced Fellowship to Dr David Metcalfe to study the diagnosis of the spinal condition, cauda equina syndrome.

Professor Chris Lavy appointed to WHO technical advisory group

Congratulations to Professor Chris Lavy, who has been appointed to the World Health Organization’s (WHO) technical advisory group for integrated clinical care for a period of two years.

Oxford receives NIHR funding to test anti-TNF on post operative delirium

Researchers at the University of Oxford have been awarded a grant from the National Institute for Health and Care Research (NIHR) to investigate whether anti-tumour necrosis factor (TNF) therapy can reduce or prevent post operative delirium/cognitive deficit.

Gene variant links trigger finger and carpal tunnel syndrome

A new NDORMS study, published in The Lancet Rheumatology, has found a genetic variant that increases the risk of both carpal tunnel syndrome and trigger finger, and opens the door for new therapies that involve blocking the IGF-1 pathway.

Kennedy programmes support early career researchers

Since 2013 the Kennedy Institute of Rheumatology has been running a Career Development Programme, a scheme to help early career researchers launch their own independent laboratories, and more recently the Innovator Investigator Programme to bring new technologies to core research themes.

OCTRU collaboration boosts understanding of COVID vaccine response

Working with researchers across multiple universities, the Oxford Clinical Trials Unit (OCTRU) played a key role in delivering results of the national VROOM trial (Vaccine Response On Off Methotrexate).